Barrington lowered the firm’s price target on Opko Health to $1.50 from $2 and keeps an Outperform rating on the shares. The company’s Q4 results included a small sales beat and a slight shortfall in terms of earnings, the analyst tells investors in a research note. The firm says BRL’s operating performance took a material step backwards in the quarter.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OPK:
- OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results
- Largest borrow rate increases among liquid names
- OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024
- OPK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Opko Health Board Member Alexis Borisy to Depart
